Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment

Despite clinical guidelines for the treatment of atrial fibrillation (AF) patient adherence to oral anticoagulants (OACs) in routine clinical practice remains low. Assessing the factors affecting adherence to the OACs regimen and developing strategies for its improvement is important.
Aim. To assess the adherence of patients with AF to the prescribed anticoagulant therapy at the outpatient stage of treatment.
Methodology. The object of the study was 165 patients with nonvalvular AF undergoing treatment in a specialized cardiology department or receiving outpatient treatment in a specialized cardiological dispensary in Saratov from February 2018 to December 2019. After 3, 6, 12 months, a telephone contact with the patients was carried out, a specially designed questionnaire was filled out, in which the anticoagulant therapy received by AF patients was reflected, the Morisky-Green questionnaire was filled out, the answers of patients about the reasons for skipping or stopping the administration of the OACs were recorded.
Results. After 3 months. 16.6 % of AF patients replaced the OACs intake with antiplatelet agents, 16 % refused antithrombotic therapy; 43.1 % of AF patients were adherent to OACs. After 6 months. antiplatelet agents were taken by 24.5 % patients (p<0.05), 11.9 % completely stopped taking antithrombotic drugs; 30.8 % of patients were adherent to OACs (p<0.05). After 12 29,5 % patients replaced OACs treatment with antiplatelet agents, 7.6 % patients did not take any antithrombotic drugs; 31.8 % of AF patients were adherent to OACs. The most common reasons for a decrease in the adherence to OACs therapy were the cost of drugs, lack of understanding of the value of OACs administration in AF, and the lack of appreciable effect of OACs administration.
Conclusion. At the outpatient stage of treatment, there was an insufficient level of adherence of AF
patients to OACs treatment.

1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russian Journal of Cardiology. 2017;(7):7–86. doi: 15829/1560-4071-2017-7-7-86

2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215. doi: 10.1161/CIRCULATIONAHA.109.192667

3. Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323. doi: 10.1016/S1474-5151(03)00091-4

4. Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013;185(2):E121–7. doi: 10.1503/cmaj.121218

5. Raparelli V, Proietti M, Buttа C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med. 2014;9(8):861—70. doi: 10.1007/s11739-014-1096-1

6. Kimmel SE, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study Arch Intern Med. 2007;167(3):229–35. doi: 10.1001/archinte.167.3.229

7. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008;6(9):1500–6. doi: 10.1111/j.1538-7836.2008.03059.x

8. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624–31. doi: 10.1161/CIRCOUTCOMES.110.937680

9. O’Brien EC, Simon DN, Allen LA, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014; 168(4):487–94. doi: 10.1016/j.ahj.2014.07.002

10. Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015;17(12):1747–69. doi: 10.1093/europace/euv233

11. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47. doi: 10.1093/eurheartj/ehs253

12. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429

13. Atrial Fibrillation: The Management of Atrial Fibrillation — PubMed — NCBI [Internet]. [cited 2021 September 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=25340239

14. Левитан А. И., Решетько О. В. Оценка приверженности больных с ревматоидным артритом медикаментозному лечению. Фармакоэкономика: теория и практика. 2016;4(1):213. [Levitan AI, Reshetko OV. Adherence to drug therapy on rheumatoid arthritis. Farmakoekonomika: teoriya i praktika. 2016;1(4):213. (In Russ).]

15. Левитан А. И., Решетько О. В. Реальная клиническая практика фармакотерапии ревматоидного артрита. Клиническая фармакология и терапия. 2019;28(1):44–9. [Levitan AI, Reshetko OV. Treatment of rheumatoid arthritis in the real-life practice. Clin Pharmacol Therapy. 2019;28(1):44–9. (In Russ).]. doi: 10.32756/0869-5490-2019-1-44-49

16. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. doi: 10.1056/NEJMoa0905561

17. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. doi: 10.1056/NEJMoa1009638

18. Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981– 92. doi: 10.1056/NEJMoa1107039

19. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. doi: 10.1056/NEJMoa1310907

20. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. doi: 10.1056/NEJMoa1007432

21. Yao X. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. doi: 10.1161/JAHA.115.003074